Top

Annals of Surgical Oncology

Published in:

01-08-2007

Heme Oxygenase-1 Gene Promoter Polymorphism is Associated with Risk of Gastric Adenocarcinoma and Lymphovascular Tumor Invasion

Authors: Su-Shun Lo, Shu-Chun Lin, Chew-Wun Wu, Jen-Hao Chen, Wen-I Yeh, Ming-Yi Chung, Win-Yiu Lui

Published in: Annals of Surgical Oncology | Issue 8/2007

Abstract

Purpose

Heme oxygenase-1 (HO-1) gene, which encodes an oxidative response protein, plays a role in cytoprotection. A (GT)_n dinucleotide repeat in HO-1 promoter is polymorphic and modulates the transcriptional activity of the gene. A HO-1 gene promoter polymorphism was reported to be associated with the risks of lung adenocarcinoma and oral squamous cancer. In this study, the correlation between the HO-1 gene promoter polymorphism and the clinicopathological characteristics, along with the risk of gastric cancer, was analyzed.

Experimental design

We examined the genotypic frequencies of (GT)_n repeats in 183 gastric cancer patients and 250 control subjects by PCR-based genotyping and DNA sequencing. The length polymorphisms of (GT)_n repeats were classified into short (S) component (n ≤ 25), medium (M) component (26 ≤ n ≤ 30) and long (L) component (n ≥ 31). The distribution of S, M and L components in patient and control groups were evaluated to determine the correlation with susceptibility and clinicopathological characteristics of gastric adenocarcinoma.

Results

Higher frequencies of L-allele, L-allele carrier (S/L, M/L, L/L) and S/L genotype were found in gastric cancer patients. The frequencies of M-allele, M-allele carrier (M/M, M/L, M/S) and M/M genotype were significantly lower in patients with gastric cancer than controls. Furthermore, the frequency of lymphovascular tumor invasion was significantly lower in M-allele carriers compared to non-M-allele carriers (S/S, S/L, L/L) (p = 0.009).

Conclusions

These findings suggest that the long (GT)_n repeat of HO-1 gene promoter was associated with a higher frequency of gastric adenocarcinoma, and the medium (GT)_n repeat might possess protective effect against gastric adenocarcinoma with a lower frequency of lymphovascular invasion in tumors.

Lee JE, Lowy AM, Thompson WA, et al. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology 1996; 111:426–32PubMedCrossRef

Ogoshi K, Tajima T, Mitomi T, Tsuji K. HLA antigens are candidate markers for prediction of lymph node metastasis in gastric cancer. Clin Exp Metastasis 1996; 14:277–81PubMed

Nabeta Y, Sahara H, Suzuki K, et al. Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma. Jpn J Cancer Res 2000; 91:616–21PubMed

Kono K, Takahashi A, Amemiya H, et al. Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int J Cancer 2002; 98:216–20PubMedCrossRef

Lo SS, Lee YJ, Wu CW, Liu CJ, Huang JW, Lui WY. The increase of MICA gene A9 allele associated with gastric cancer and less schirrous change. Br J Cancer 2004; 90:1809–13PubMed

Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988; 2:2557–68PubMed

Motterlini R, Foresti R, Bassi R, Calabrese V, Clark JE, Green CJ. Endothelial heme oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxide synthase and S-nitrosothiols. J Biol Chem 2000; 275:13613–20PubMedCrossRef

Shibahara S. Regulation of heme oxygenase gene expression. Semin Hematol 1988; 25:370–6PubMed

Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989; 86:99–103PubMedCrossRef

10.

Oguro T, Hayashi M, Numazawa S, Asakawa K, Yoshida T. Heme oxygenase-1 gene expression by a glutathione depletor, phorone, mediated through AP-1 activation in rats. Biochem Biophys Res Commun 1996; 221:259–65PubMedCrossRef

11.

Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 1999; 80:1945–54PubMedCrossRef

12.

Maines MD, Abrahamsson PA. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 1996; 47:727–33PubMedCrossRef

13.

Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 1997; 214:54–61PubMed

14.

Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene 2004; 23:503–13PubMedCrossRef

15.

Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 2003; 63:3567–74PubMed

16.

Sunamura M, Duda DG, Ghattas MH, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6:15–24PubMedCrossRef

17.

Kutty RK, Kutty G, Rodriguez IR, Chader GJ, Wiggert B. Chromosomal localization of the human heme oxygenase genes: heme oxygenase-1 (HMOX1) maps to chromosome 22q12 and heme oxygenase-2 (HMOX2) maps to chromosome 16p13.3. Genomics 1994; 20:513–6PubMedCrossRef

18.

Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci USA 1994; 91: 5987–91PubMedCrossRef

19.

Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157:1770–8PubMed

20.

Ono K, Mannami T, Iwai N. Association of a promoter variant of the haeme oxygenase-1 gene with hypertension in women. J Hypertens 2003; 21:1497–503PubMedCrossRef

21.

Kaneda H, Ohno M, Taguchi J, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002; 22:1680–5PubMedCrossRef

22.

Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111:1–8PubMedCrossRef

23.

Baan C, Peeters A, Lemos F, et al. Fundamental role for HO-1 in the self-protection of renal allografts. Am J Transplant 2004; 4:811–88PubMedCrossRef

24.

Exner M, Bohmig GA, Schillinger M, et al. Donor heme oxygenase-1 genotype is associated with renal allograft function. Transplantation 2004; 77:538–42PubMedCrossRef

25.

Denschlag D, Marculescu R, Unfried G, et al. The size of a microsatellite polymorphism of the haem oxygenase 1 gene is associated with idiopathic recurrent miscarriage. Mol Hum Reprod 2004; 10:211–4PubMedCrossRef

26.

Kimpara T, Takeda A, Watanabe K, et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet 1997; 100:145–7PubMedCrossRef

27.

Hirai H, Kubo H, Yamaya M, et al. Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. Blood 2003; 102:1619–21PubMedCrossRef

28.

Kanai M, Akaba K, Sasaki A, et al. Neonatal hyperbilirubinemia in Japanese neonates: analysis of the heme oxygenase-1 gene and fetal hemoglobin composition in cord blood. Pediatr Res 2003; 54:165–71PubMedCrossRef

29.

Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66:187–95PubMedCrossRef

30.

Kikuchi A, Yamaya M, Suzuki S, et al. Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet 2005; 116:354–60PubMedCrossRef

31.

Chang KW, Lee TC, Yeh WI, Chung MY, Liu CJ, Chi LY, Lin SC. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer 2004; 91:1551–5PubMedCrossRef

32.

Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma, 1st English edn. Tokyo: Kanehara Shuppan, 1995

33.

Agoresti A. An Introduction to Categorical Data Analysis. New York: Wiley, 1996: p. 24

34.

Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004; 37:1097–104PubMedCrossRef

35.

Tulis DA, Durante W, Peyton KJ, Evans AJ, Schafer AI. Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis 2001; 155:113–22PubMedCrossRef

36.

Duckers HJ, Boehm M, True AL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001; 7:693–8PubMedCrossRef

37.

Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, Lusis AJ. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 2001; 88:506–12PubMed

38.

Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969; 244:6388–94

39.

Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235:1043–6PubMedCrossRef

40.

Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992; 267:18148–53PubMed

41.

Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science 1993; 259:381–4PubMedCrossRef

42.

Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001; 8:433–40PubMedCrossRef

43.

Furchgott RF, Jothianandan D. Endothelium-dependent, -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels 1991; 28:52–61PubMed

44.

Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32:497–504PubMed

45.

Morita T, Perrella MA, Lee ME, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci USA 1995; 92:1475–9PubMedCrossRef

46.

Wang R, Wu L, Wang Z. The direct effect of carbon monoxide on KCa channels in vascular smooth muscle cells. Pflugers Arch 1997; 434:285–91PubMedCrossRef

47.

Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2:58–60PubMedCrossRef

48.

Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol 2002; 55:770–3PubMedCrossRef

49.

Coma del Corral MJ, Pardo-Mindan FJ, Razquin S, Ojeda C. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 1990; 65:2078–85

Title: Heme Oxygenase-1 Gene Promoter Polymorphism is Associated with Risk of Gastric Adenocarcinoma and Lymphovascular Tumor Invasion
Authors: Su-Shun Lo
Shu-Chun Lin
Chew-Wun Wu
Jen-Hao Chen
Wen-I Yeh
Ming-Yi Chung
Win-Yiu Lui
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9290-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Heme Oxygenase-1 Gene Promoter Polymorphism is Associated with Risk of Gastric Adenocarcinoma and Lymphovascular Tumor Invasion

Abstract

Purpose

Experimental design

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2007

Resecting Lymph Nodes in Colon Cancer: More than a Staging Operation?

Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Sentinel Lymph Node Biopsy for DCIS: Are We Approaching Consensus?

Comparing Surgical Outcomes in Obese Women Undergoing Laparotomy, Laparoscopy, or Laparotomy With Panniculectomy for the Staging of Uterine Malignancy

Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS?

Surgical Management and Outcome in Primary Adenocarcinoma of the Small Bowel